Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) Profit After Tax: 2013-2025

Historic Profit After Tax for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to -$2.7 million.

  • MediWound's Profit After Tax rose 74.21% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year increase of 26.57%. This contributed to the annual value of -$30.2 million for FY2024, which is 350.03% down from last year.
  • As of Q3 2025, MediWound's Profit After Tax stood at -$2.7 million, which was up 80.09% from -$13.3 million recorded in Q2 2025.
  • Over the past 5 years, MediWound's Profit After Tax peaked at $4.4 million during Q2 2022, and registered a low of -$13.3 million during Q2 2025.
  • In the last 3 years, MediWound's Profit After Tax had a median value of -$3.7 million in 2023 and averaged -$4.9 million.
  • In the last 5 years, MediWound's Profit After Tax surged by 236.28% in 2022 and then tumbled by 788.32% in 2024.
  • Quarterly analysis of 5 years shows MediWound's Profit After Tax stood at -$4.2 million in 2021, then tumbled by 79.25% to -$7.5 million in 2022, then surged by 76.63% to -$1.7 million in 2023, then crashed by 124.21% to -$3.9 million in 2024, then surged by 74.21% to -$2.7 million in 2025.
  • Its Profit After Tax stands at -$2.7 million for Q3 2025, versus -$13.3 million for Q2 2025 and -$726,000 for Q1 2025.